Summary

As type 1 diabetes continues to be a worldwide epidemic, researchers persist in exploring new ways to prevent the disease from developing or to delay its development, especially in young children. Several studies have evaluated the safety and efficacy of immunomodulatory therapies, both as prevention strategies and as interventions for new-onset disease.